Green pharmacy in antibiotic development: prolonging efficacy by prioritising compounds least likely to select for resistance

Dr Aimee Murray
NERC Industrial Innovation Research Fellow
ABX Meeting, Eden Project 11th – 12th July 2019
We are looking for collaborators!

Able to provide abandoned compounds or those currently under development for testing.
Antibiotics are high risk, low profit

- Drugs take years to develop – cost
- Antibiotics are for acute illnesses – low return
  - Short term prescription only
  - Less return than for e.g. hypertension drugs, or other chronic conditions
- They soon become ineffective due to novel resistances arising

... The concepts of the green pharmacy... numerous approaches can be used to not only reduce or minimize the entry of APIs to the environment, but to simultaneously improve the efficiency and effectiveness of healthcare... with outcomes such as lower costs for the consumer, improved therapeutic outcomes and reduced incidence of unintended poisonings and drug diversion.

‘Selective Assay for Growth-based Endpoints’

SAGE method for Green Pharmacy in antibiotic development

Thank you for your attention

Any questions?

a.k.murray@exeter.ac.uk

@AimeeKMurray